About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China

News

Study Met Primary Endpoint; AIMS Response Rate Reached 76.5% in the 20mg Dose Group Shanghai, June 16, 2026 -- Luye Pharma Group today announced that a Phase 2 clinical trial in China evaluating its LY03015 in patients with tardive dyskinesia ...

June 16,2026

Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015

Shanghai, April 20th, 2026 — Luye Pharma Group today announced that the first subject has been enrolled in a U.S. pharmacokinetic (PK) bridging clinical trial of its new molecular entity LY03015. This is the world’s first ...

April 20,2026

Read More

Investors

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company